ENZN
Viskase Companies, Inc.
Set alert
4.71 USD 0.00 0.00%
4.35 Day range 4.71
0.35 52-week range 0.88
- YTD
- +11,675.00%
- 1 year
- +4,610.00%
- Open
- 4.35
- Prev close
- 4.71
- Mkt cap
- 19.83M
- Vol
- 1.30K
- Avg vol
- 177.28K
- EPS
- 0.36
- P/E
- 1.25
- Div yield
- 0.00%
More statistics
- Low
- 4.35
- High
- 4.71
- Forward P/E
- 0.00
- Beta
- 1.18
- Short ratio
- 1.03
- Inst. own
- 46.30%
- Dividend
- 0.00
- Ex-div date
- Dec 29, 2015
- 50-d avg
- 0.398857
- 200-d avg
- 0.390429
- 1y target
- 14.00
Key statistics
- Market cap
- 19.83M
- Enterprise value
- 6.56M
- Trailing P/E
- 1.25
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 1.86
- Price / book
- 0.92
- EPS (TTM)
- 0.36
- Beta
- 1.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 150.08%
- Revenue (TTM)
- 10.65M
- Revenue growth
- -47.80%
- Free cash flow
- 670.13K
- Total cash
- 12.90M
- Total debt
- 0
- Return on equity
- 83.64%
- Shares outstanding
- 44.21M
- Short % of float
- 0.41%
- 50-day average
- 0.398857
- 200-day average
- 0.390429
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ENZN Revenue — quarterly 0
ENZN Net income — quarterly 183.00K
ENZN EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Mar 20, 2024 | Dec 1, 2023 | 0.00 | 0.01 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 7, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 28, 2010 | Caris & Company | down | Above Average | Average |
| May 4, 2010 | C.K. Cooper | init | — | Buy |
| Dec 9, 2008 | Caris & Company | init | — | Buy |
| Sep 9, 2008 | Oppenheimer | init | — | Outperform |
| Jul 10, 2006 | BMO Nesbitt Burns | init | — | Market Perform |
| Apr 20, 2005 | Sun Trust Rbsn Humphrey | down | Buy | Neutral |
About Viskase Companies, Inc.
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohns disease. The company was founded in 1981 and is based in Cranford, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- enzon.com
News
Your note
Sign in to keep a note on ENZN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PanAgora Asset Management, Inc. | 0.12% | 51,280 | 18.97K | Sep 29, 2016 |
| Tudor Investment Corporation | 0.11% | 47,998 | 17.76K | Sep 29, 2016 |
| Monarch Capital Management Inc. | 0.02% | 10,000 | 3.70K | Sep 29, 2016 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Funds-Small Cap Growth Equity Portfolio | 1.24% | 545,226 | 223.54K | Jun 29, 2016 |
| Blackrock Master Tr-Blackrock Master Small Cap Growth Port | 0.25% | 107,723 | 40.93K | Aug 30, 2016 |
| Bridgeway Fds Inc.-Omni Tax Managed Small Cap Value Fund | 0.21% | 93,500 | 38.34K | Jun 29, 2016 |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | 0.14% | 60,300 | 24.72K | Jun 29, 2016 |
| BlackRock Disciplined Small Cap Core Fund | 0.02% | 8,051 | 3.06K | Aug 30, 2016 |